Cochrane Review Group

Hypertension

56 systematic reviews in Hypertension ask 535 questions. 6.9% have no studies to answer them, 17% rest on very low certainty evidence and 39.6% reach moderate or high certainty.

Reviews

Questions

535

current versions

No studies

6.9%

Moderate or high

39.6%

No studies 37 · 6.9%Ungraded 34 · 6.4%Very low 91 · 17%Low 161 · 30.1%Moderate 136 · 25.4%High 76 · 14.2%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Hypertension

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Evening vs morning dosing regimen All‐cause mortality · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	RR 0.49 [0.04, 5.42]	1 study · 735 participants	Very low
Evening vs morning dosing regimen Cardiovascular mortality (time points not specified) · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	no estimate extracted	NR	No studies
Evening vs morning dosing regimen Cardiovascular morbidity (stroke, myocardial infarction, congestive heart failure, aortic aneurysm) (time points not specified) · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	no estimate extracted	NR	No studies
Evening vs morning dosing regimen Serious adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	RR 1.17 [0.53, 2.57]	2 studies · 833 participants	Very low
Evening vs morning dosing regimen Overall adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	RR 0.89 [0.67, 1.2]	7 studies · 1541 participants	Very low
Evening vs morning dosing regimen Withdrawals from treatment due to adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80… Evening versus morning dosing regimen drug therapy for hypertension (2024) · Cochrane	RR 0.76 [0.47, 1.23]	7 studies · 1777 participants	Very low
First‐line thiazides vs first‐line ACE inhibitors Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane	no estimate extracted	NR	No studies
First‐line thiazides vs first‐line beta‐blockers Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane	no estimate extracted	NR	No studies
First‐line thiazides vs first‐line alpha‐blockers Total serious adverse events · adults with hypertension First‐line diuretics versus other classes of antihypertensive drugs for hypertension (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Pravastatin 10 to 80 mg/day (6 to 156 weeks) · participants with normal or abnormal lipid profiles Pravastatin for lowering lipids (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR WDAEs · participants with normal or abnormal lipid profiles Pravastatin for lowering lipids (2023) · Cochrane	RR 0.81 [0.63, 1.03]	33 studies · 6187 participants	Very low
Calcium supplementation/fortification vs control Adverse events (secondary outcome) · People who may be at risk for primary hypertension Calcium supplementation for prevention of primary hypertension (2022) · Cochrane	no estimate extracted	NR	No studies

Reviews 56

Evening versus morning dosing regimen drug therapy for hypertension

Wu, C, Zhao, P, et al. · Cochrane Database of Systematic Reviews · 2024

Hypertension

Thinnest evidence

Reviews 56

Evening versus morning dosing regimen drug therapy for hypertension

First‐line diuretics versus other classes of antihypertensive drugs for hypertension

Pravastatin for lowering lipids

Antiplatelet agents and anticoagulants for hypertension

Calcium channel blockers versus other classes of drugs for hypertension

Calcium supplementation for prevention of primary hypertension

Blood pressure targets for the treatment of people with hypertension and cardiovascular disease

Long‐term effects of weight‐reducing drugs in people with hypertension

Roselle for hypertension in adults

Long‐term effects of weight‐reducing diets in people with hypertension

Walking for hypertension

Effect of periodontal treatments on blood pressure

Renal denervation for resistant hypertension

Pharmacotherapy for hypertension‐induced left ventricular hypertrophy

Effect of atorvastatin on testosterone levels

Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride

Blood pressure targets in adults with hypertension

Pharmacotherapy for hyperuricaemia in hypertensive patients

Alcohol intake reduction for controlling hypertension

Time course for blood pressure lowering of beta‐blockers with partial agonist activity

First‐line combination therapy versus first‐line monotherapy for primary hypertension

Cerivastatin for lowering lipids

Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension

Withdrawal of antihypertensive drugs in older people

Pitavastatin for lowering lipids